Drug Trial Radar · NCT05791318
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: May 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 28, 2023
Primary completion
May 8, 2024
Study completion May 8, 2024
Sponsor
- Lead sponsor
- Invivyd, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Mar 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to investigate the safety, tolerability, and pharmacokinetics of the monoclonal antibody VYD222 in healthy adult participants.
Conditions
- COVID-19
Interventions
VYD222Drug
Monoclonal antibody
PlaceboOther
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAEs (including AEs and SAEs)Time frame: Through 12 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research
Joondalup, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.